These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 29288421

  • 1. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R, Bergamaschini L, Deliliers GL.
    Med Oncol; 2017 Dec 29; 35(2):15. PubMed ID: 29288421
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C.
    Br J Haematol; 2018 Dec 29; 183(5):755-765. PubMed ID: 30407629
    [Abstract] [Full Text] [Related]

  • 3. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A, Argnani L, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Casadei B, Sabattini E, Cavo M, Zinzani PL.
    Hematol Oncol; 2020 Oct 29; 38(4):487-492. PubMed ID: 32594531
    [Abstract] [Full Text] [Related]

  • 4. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
    Cervetti G, Ghio F, Cecconi N, Morganti R, Galimberti S, Petrini M.
    J Chemother; 2017 Apr 29; 29(2):126-129. PubMed ID: 27454143
    [Abstract] [Full Text] [Related]

  • 5. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
    Scapinello G, Pizzi M, Vio S, Nabergoj M, Visentin A, Martines A, Bonaldi L, Trentin L, Semenzato G, Piazza F.
    Ann Hematol; 2018 Oct 29; 97(10):2001-2003. PubMed ID: 29728736
    [No Abstract] [Full Text] [Related]

  • 6. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.
    Hematology; 2017 Aug 29; 22(7):405-411. PubMed ID: 28105889
    [Abstract] [Full Text] [Related]

  • 7. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
    Perrone S, D'Elia GM, Annechini G, Ferretti A, Tosti ME, Foà R, Pulsoni A.
    Leuk Res; 2016 May 29; 44():53-60. PubMed ID: 27030961
    [Abstract] [Full Text] [Related]

  • 8. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M.
    Ann Oncol; 2013 Sep 29; 24(9):2434-8. PubMed ID: 23712547
    [Abstract] [Full Text] [Related]

  • 9. Risk-tailored treatment of splenic marginal zone lymphoma.
    Castelli R, Balzarotti M, Salvi E, Simona Rossi R, Lambertenghi Deliliers G, Bergamaschini L, Gidaro A.
    Anticancer Drugs; 2022 Jan 01; 33(1):e36-e42. PubMed ID: 34407041
    [Abstract] [Full Text] [Related]

  • 10. Splenic marginal zone lymphoma: from genetics to management.
    Arcaini L, Rossi D, Paulli M.
    Blood; 2016 Apr 28; 127(17):2072-81. PubMed ID: 26989207
    [Abstract] [Full Text] [Related]

  • 11. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C.
    Haematologica; 2024 Jul 01; 109(7):2297-2302. PubMed ID: 38497158
    [No Abstract] [Full Text] [Related]

  • 12. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
    Laribi K, Tempescul A, Ghnaya H, Denizon N, Besançon A, Anghel A, Farhi J, Truong C, Lemaire P, Poulain S, Bolle D, Ianotto JC, Baugier de Materre A.
    Hematol Oncol; 2017 Dec 01; 35(4):536-541. PubMed ID: 27443419
    [Abstract] [Full Text] [Related]

  • 13. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
    Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, Incardona P, Brusamolino E, Passamonti F, Burcheri S, Schena C, Pascutto C, Cavanna L, Magrini U, Lazzarino M.
    Cancer; 2004 Jan 01; 100(1):107-15. PubMed ID: 14692030
    [Abstract] [Full Text] [Related]

  • 14. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL, Cabanillas F, Rivera N, Tirado-Gomez M, Hallman D, Pardo WI, Bruno M.
    Clin Lymphoma Myeloma Leuk; 2017 Dec 01; 17(12):879-883. PubMed ID: 29042174
    [Abstract] [Full Text] [Related]

  • 15. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
    Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S.
    Oncol Res; 2024 Dec 01; 32(6):1031-1036. PubMed ID: 38827319
    [Abstract] [Full Text] [Related]

  • 16. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
    Mulas O, Caocci G, Dessì D, Mantovani D, Moi G, Cabras MG, La Nasa G.
    Acta Haematol; 2021 Dec 01; 144(3):322-326. PubMed ID: 32892194
    [Abstract] [Full Text] [Related]

  • 17. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
    de Pádua Covas Lage LA, Dos Santos FFC, Levy D, Moreira FR, Couto SCF, Culler HF, de Oliveira Costa R, Rocha V, Pereira J.
    BMC Cancer; 2020 Aug 03; 20(1):717. PubMed ID: 32746790
    [Abstract] [Full Text] [Related]

  • 18. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD.
    Lancet Oncol; 2016 Aug 03; 17(8):1081-1093. PubMed ID: 27345636
    [Abstract] [Full Text] [Related]

  • 19. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
    Olszewski AJ, Ali S.
    Ann Hematol; 2014 Mar 03; 93(3):449-58. PubMed ID: 24057925
    [Abstract] [Full Text] [Related]

  • 20. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M, Schechter GP.
    Semin Hematol; 2010 Apr 03; 47(2):143-7. PubMed ID: 20350661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.